US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US20040226056A1
(en)
*
|
1998-12-22 |
2004-11-11 |
Myriad Genetics, Incorporated |
Compositions and methods for treating neurological disorders and diseases
|
BR0007532A
(pt)
|
1999-01-13 |
2001-11-20 |
Univ New York State Res Found |
Métodos para identificar inibidores de proteìnaquinase, para testar compostos para umacapacidade de inibir a atividade de proteìnaquinase e para inibir uma proteìna quinase, inibidorde proteìna tirosina quinase não peptìdica, e,método de tratar uma condição responsiva a uminibidor de proteìna quinase em um paciente
|
BRPI0108394B8
(pt)
*
|
2000-02-15 |
2021-05-25 |
Upjohn Co |
inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
MY128450A
(en)
|
2000-05-24 |
2007-02-28 |
Upjohn Co |
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
JP2003535847A
(ja)
|
2000-06-02 |
2003-12-02 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ/ホスファターゼ阻害剤としてのインドリノン誘導体
|
EP1296975A1
(en)
*
|
2000-06-30 |
2003-04-02 |
Sugen, Inc. |
4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
|
MX242553B
(es)
|
2000-10-20 |
2006-12-06 |
Eisai Co Ltd |
Derivados aromaticos que contienen nitrogeno.
|
EP1349852A2
(en)
*
|
2000-12-20 |
2003-10-08 |
Sugen, Inc. |
4-(hetero)aryl substituted indolinones
|
AR042586A1
(es)
*
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
EP1247809A3
(en)
*
|
2001-03-30 |
2003-12-17 |
Pfizer Products Inc. |
Triazine compounds useful as sorbitol dehydrogenase inhibitors
|
WO2002096361A2
(en)
|
2001-05-30 |
2002-12-05 |
Sugen, Inc. |
5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
DE60227709D1
(de)
*
|
2001-06-29 |
2008-08-28 |
Ab Science |
Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
|
DK3168218T3
(en)
|
2001-08-15 |
2019-01-14 |
Pharmacia & Upjohn Co Llc |
Crystalline comprising an L-malic acid salt of N- [2- (DIETHYLAMINO) ETHYL] -5 - [(5-FLUOR-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE) METHYL] -2,4 -DIMETHYL-1H-PYRROL-3-CARBOXAMIDE FOR USE AS A MEDICINE
|
AR038957A1
(es)
*
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
EP1436259A1
(en)
|
2001-09-10 |
2004-07-14 |
Congxin Liang |
3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
|
US6642232B2
(en)
*
|
2001-10-10 |
2003-11-04 |
Sugen, Inc. |
3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
US7129225B2
(en)
*
|
2001-10-22 |
2006-10-31 |
The Research Foundation Of State University Of New York |
Protection against and treatment of hearing loss
|
US20030080191A1
(en)
*
|
2001-10-26 |
2003-05-01 |
Allen Lubow |
Method and apparatus for applying bar code information to products during production
|
TWI259081B
(en)
*
|
2001-10-26 |
2006-08-01 |
Sugen Inc |
Treatment of acute myeloid leukemia with indolinone compounds
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
EP1466297A4
(en)
*
|
2001-12-17 |
2005-10-19 |
Int Barcode Corp |
AS A SINGLE CODE, DOUBLE-SIDED CODE
|
US20050131733A1
(en)
*
|
2001-12-17 |
2005-06-16 |
Allen Lubow |
Sealable individual bar coded packets
|
AU2002360753B2
(en)
|
2001-12-27 |
2008-08-21 |
Theravance, Inc. |
Indolinone derivatives useful as protein kinase inhibitors
|
EP1476443A2
(en)
|
2002-02-15 |
2004-11-17 |
PHARMACIA & UPJOHN COMPANY |
Process for preparing indolinone derivatives
|
AU2003233576A1
(en)
*
|
2002-05-17 |
2003-12-02 |
Sugen, Inc. |
Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
|
ITMI20021620A1
(it)
*
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
WO2004016211A2
(en)
*
|
2002-08-08 |
2004-02-26 |
Vanderbilt University |
Pi3k antagonists as radiosensitizers
|
AU2003259713A1
(en)
*
|
2002-08-09 |
2004-02-25 |
Theravance, Inc. |
Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
|
US20040121407A1
(en)
*
|
2002-09-06 |
2004-06-24 |
Elixir Pharmaceuticals, Inc. |
Regulation of the growth hormone/IGF-1 axis
|
TW200418836A
(en)
*
|
2002-09-10 |
2004-10-01 |
Pharmacia Italia Spa |
Formulations comprising an indolinone compound
|
WO2004050681A2
(en)
*
|
2002-11-15 |
2004-06-17 |
Exelixis, Inc. |
Kinase modulators
|
AR042042A1
(es)
*
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
US7452913B2
(en)
*
|
2003-02-24 |
2008-11-18 |
Pharmacia & Upjohn Company |
Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
|
US20040209937A1
(en)
*
|
2003-02-24 |
2004-10-21 |
Sugen, Inc. |
Treatment of excessive osteolysis with indolinone compounds
|
PT1603570E
(pt)
|
2003-02-26 |
2013-03-26 |
Sugen Inc |
Compostos de aminoheteroarilo como inibidores da proteína quinase
|
US20040266843A1
(en)
*
|
2003-03-07 |
2004-12-30 |
Sugen, Inc. |
Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
|
US7157577B2
(en)
*
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
ATE508747T1
(de)
*
|
2003-03-10 |
2011-05-15 |
Eisai R&D Man Co Ltd |
C-kit kinase-hemmer
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
DE10334582A1
(de)
*
|
2003-07-28 |
2005-02-24 |
Basf Ag |
Verfahren zur Herstellung von Maleinsäureanhydrid
|
WO2005023765A1
(en)
*
|
2003-09-11 |
2005-03-17 |
Pharmacia & Upjohn Company Llc |
Method for catalyzing amidation reactions by the presence of co2
|
JP4933259B2
(ja)
*
|
2003-10-02 |
2012-05-16 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
ピロール置換インドリノン化合物の塩および多形
|
CA2542638A1
(en)
*
|
2003-10-16 |
2005-04-28 |
Imclone Systems Incorporated |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
EP1682529A4
(en)
|
2003-11-07 |
2010-06-30 |
Novartis Vaccines & Diagnostic |
METHODS FOR SYNTHESIS OF QUINOLINONE COMPOUNDS
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
AU2004294981A1
(en)
*
|
2003-11-26 |
2005-06-16 |
The Scripps Research Institute |
Advanced indolinone based protein kinase inhibitors
|
JP2007513967A
(ja)
*
|
2003-12-11 |
2007-05-31 |
セラヴァンス, インコーポレーテッド |
変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
|
US20050152943A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Medtronic Vascular, Inc. |
Medical devices to treat or inhibit restenosis
|
WO2005118543A1
(ja)
*
|
2004-06-03 |
2005-12-15 |
Ono Pharmaceutical Co., Ltd. |
キナーゼ阻害薬およびその用途
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
SE0401790D0
(sv)
*
|
2004-07-07 |
2004-07-07 |
Forskarpatent I Syd Ab |
Tamoxifen response in pre- and postmenopausal breast cancer patients
|
US20060009510A1
(en)
*
|
2004-07-09 |
2006-01-12 |
Pharmacia & Upjohn Company Llc |
Method of synthesizing indolinone compounds
|
ATE463486T1
(de)
*
|
2004-08-26 |
2010-04-15 |
Pfizer |
Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
|
CN101001629B
(zh)
|
2004-09-17 |
2010-05-05 |
卫材R&D管理有限公司 |
药物组合物
|
CN100432071C
(zh)
*
|
2004-11-05 |
2008-11-12 |
中国科学院上海药物研究所 |
取代1h-吲哚-2-酮类化合物及其制备方法和用途
|
GT200500321A
(es)
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
RU2007135167A
(ru)
*
|
2005-03-23 |
2009-03-27 |
Пфайзер Продактс Инк. (Us) |
Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака
|
EP1877444A2
(en)
|
2005-04-26 |
2008-01-16 |
Pfizer, Inc. |
P-cadherin antibodies
|
BRPI0609957A2
(pt)
*
|
2005-05-12 |
2010-05-11 |
Pfizer |
uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer
|
EP2361905B1
(en)
|
2005-05-18 |
2013-03-06 |
Array Biopharma Inc. |
Heterocyclic Inhibitors of MEK and methods of use thereof
|
AU2006249847B2
(en)
|
2005-05-23 |
2012-12-20 |
Novartis Ag |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
|
JP2008542294A
(ja)
*
|
2005-05-26 |
2008-11-27 |
ザ スクリプス リサーチ インスティテュート |
向上したインドリノン系プロテインキナーゼ阻害剤
|
EP1925941B1
(en)
*
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
PL1933871T3
(pl)
|
2005-09-07 |
2013-09-30 |
Amgen Fremont Inc |
Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do recepora aktywiny-1
|
CA2621569C
(en)
|
2005-09-19 |
2010-10-19 |
Pfizer Products Inc. |
Solid salt forms of a pyrrole substituted 2-indolinone
|
EP1949902B1
(en)
*
|
2005-11-07 |
2012-06-27 |
Eisai R&D Management Co., Ltd. |
USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
CN101389331A
(zh)
*
|
2005-12-29 |
2009-03-18 |
斯克里普斯研究学院 |
基于吲哚满酮的氨基酸衍生物的蛋白激酶抑制剂
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
CN101007801A
(zh)
*
|
2006-01-27 |
2007-08-01 |
上海恒瑞医药有限公司 |
吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CA2648809A1
(en)
|
2006-04-19 |
2007-11-01 |
Novartis Ag |
Indazole compounds and methods for inhibition of cdc7
|
WO2007132307A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
WO2007136103A1
(ja)
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
DE102006024834B4
(de)
*
|
2006-05-24 |
2010-07-01 |
Schebo Biotech Ag |
Neue Indol-Pyrrol-Derivate und deren Verwendungen
|
EP2044939A1
(en)
*
|
2006-06-29 |
2009-04-08 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for liver fibrosis
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
WO2008008981A1
(en)
|
2006-07-13 |
2008-01-17 |
Zymogenetics, Inc. |
Interleukin 21 and tyrosine kinase inhibitor combination therapy
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
US8044049B2
(en)
|
2006-08-04 |
2011-10-25 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic derivative and use thereof
|
DK2057156T3
(en)
|
2006-08-23 |
2017-05-08 |
Kudos Pharm Ltd |
2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
|
EP2065372B1
(en)
*
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
AU2007294686B2
(en)
|
2006-09-15 |
2013-10-31 |
Equinox Sciences, Llc |
Kinase inhibitor compounds
|
EP2130829A4
(en)
*
|
2006-11-06 |
2010-12-01 |
Theravalues Corp |
NEW HYDROXYINDOLE DERIVATIVE
|
KR101546493B1
(ko)
|
2006-11-06 |
2015-08-21 |
톨레로 파마수티컬스, 인크. |
이미다조[1,2-b]피리다진 및 피라졸로[1,5-a]피리미딘 유도체 및 단백질 키나제 억제제로서의 이의 용도
|
ES2383084T3
(es)
|
2006-12-04 |
2012-06-18 |
Jiangsu Simcere Pharmaceutical R&D Co., Ltd. |
Derivados de 3-pirrolo[b]ciclohexilen-2-dihidroindolinona y usos de los mismos
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
JP4523073B2
(ja)
|
2007-02-06 |
2010-08-11 |
ファイザー・インク |
癌を治療するためのHSP−90阻害剤としての2−アミノ−5,7−ジヒドロ−6H−ピロロ[3,4−d]ピリミジン誘導体
|
JPWO2008114819A1
(ja)
|
2007-03-20 |
2010-07-08 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
US20090004213A1
(en)
|
2007-03-26 |
2009-01-01 |
Immatics Biotechnologies Gmbh |
Combination therapy using active immunotherapy
|
US20090042906A1
(en)
*
|
2007-04-26 |
2009-02-12 |
Massachusetts Institute Of Technology |
Methods for treating cancers associated with constitutive egfr signaling
|
WO2008138184A1
(fr)
|
2007-05-14 |
2008-11-20 |
Shanghai Hengrui Pharmaceutical Co.Ltd. |
Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
|
WO2008145398A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Pfizer Italia S.R.L. |
4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
|
JP5352476B2
(ja)
|
2007-06-05 |
2013-11-27 |
武田薬品工業株式会社 |
キナーゼ阻害剤としての二環式複素環化合物
|
EP2181987B9
(en)
|
2007-08-23 |
2014-09-03 |
Takeda Pharmaceutical Company Limited |
2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
|
US20090062368A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
ES2759347T3
(es)
*
|
2007-09-06 |
2020-05-08 |
Boston Biomedical Inc |
Composiciones de inhibidores de quinasas y su uso para el tratamiento del cáncer y otras enfermedades relacionadas con las quinasas
|
PL2201012T3
(pl)
|
2007-10-11 |
2014-11-28 |
Astrazeneca Ab |
Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
|
EP2218712B1
(en)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
US20100256392A1
(en)
*
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
CA2699306A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
|
US8389562B2
(en)
*
|
2007-12-12 |
2013-03-05 |
Medichem, S.A. |
Polymorphic forms of a 3-pyrrole substituted 2-indolinone
|
PL2222675T3
(pl)
|
2007-12-19 |
2014-02-28 |
Genentech Inc |
5-anilinoimidazopirydyny i sposoby zastosowania
|
US8940771B2
(en)
|
2007-12-20 |
2015-01-27 |
Novartis Ag |
Organic compounds
|
JP5710269B2
(ja)
|
2007-12-21 |
2015-04-30 |
ジェネンテック, インコーポレイテッド |
アザインドリジン類と使用方法
|
MX2010008187A
(es)
*
|
2008-01-29 |
2010-08-10 |
Eisai R&D Man Co Ltd |
Uso combinado de inhibidor de angiogenesis y taxano.
|
EP2090306A1
(en)
|
2008-02-13 |
2009-08-19 |
Ratiopharm GmbH |
Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
EP2240174A1
(en)
*
|
2008-02-13 |
2010-10-20 |
Ratiopharm GmbH |
Pharmaceutical compositions comprising n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide
|
EP2113248A1
(en)
|
2008-04-29 |
2009-11-04 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
|
CN101255154B
(zh)
*
|
2008-02-18 |
2011-09-07 |
靳广毅 |
一种取代的2-吲哚啉酮衍生物和制备方法及其应用
|
EP2252607A2
(en)
*
|
2008-02-21 |
2010-11-24 |
Generics [UK] Limited |
Novel polymorphs and processes for their preparation
|
EP2098521A1
(en)
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
WO2009124037A1
(en)
*
|
2008-03-31 |
2009-10-08 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing sunitinib and salts thereof
|
US8466190B2
(en)
|
2008-04-16 |
2013-06-18 |
Natco Pharma Limited |
Polymorphic forms of Sunitinib base
|
US8158656B2
(en)
*
|
2008-05-16 |
2012-04-17 |
Shenzhen Chipscreen Biosciences Ltd. |
2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
US8829039B2
(en)
|
2008-05-23 |
2014-09-09 |
Shanghai Institute Of Pharmaceutical Industry |
Dihydroindolinone derivatives
|
US8263547B2
(en)
*
|
2008-05-28 |
2012-09-11 |
Massachusetts Institute Of Technology |
DISC-1 pathway activators in the control of neurogenesis
|
SI2313371T1
(sl)
*
|
2008-06-13 |
2013-02-28 |
Medichem, S.A. |
Postopek za pripravo soli 3-pirol substituirane 2-indolinonske jabolčne kisline
|
KR20110036055A
(ko)
*
|
2008-06-23 |
2011-04-06 |
낫코 파마 리미티드 |
고순도의 수니티닙 및 이의 약학적으로 허용가능한 염의 개선된 제조 방법
|
EP2138167A1
(en)
*
|
2008-06-24 |
2009-12-30 |
ratiopharm GmbH |
Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
WO2009156837A2
(en)
*
|
2008-06-26 |
2009-12-30 |
Medichem, S.A. |
Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
|
EP2294184A4
(en)
|
2008-06-30 |
2013-03-06 |
Mesoblast Inc |
TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
|
DE102008031038A1
(de)
|
2008-06-30 |
2009-12-31 |
Alexander Priv.-Doz. Dr. Dömling |
Sutent zur Anwendung in der Organtransplantation
|
CA2729745A1
(en)
*
|
2008-06-30 |
2010-01-07 |
Cylene Pharmaceuticals, Inc. |
Oxindole compounds
|
AU2009265360A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Generics [Uk] Limited |
Preparation of 3-pyrrole substituted 2-indolinone derivatives
|
EP2297138A1
(en)
*
|
2008-07-10 |
2011-03-23 |
Generics [UK] Limited |
Processes for the preparation of crystalline forms of sunitinib malate
|
KR20110036588A
(ko)
|
2008-07-24 |
2011-04-07 |
테바 파마슈티컬 인더스트리즈 리미티드 |
수니티닙 아세테이트 및 이의 다형을 통한 수니티닙 말레이트의 제조 방법
|
WO2010010454A2
(en)
|
2008-07-24 |
2010-01-28 |
Medichem, S.A. |
Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
|
US8993615B2
(en)
*
|
2008-08-08 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
CA2735006A1
(en)
*
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Pd-1 antagonists and methods of use thereof
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
JP2012500838A
(ja)
*
|
2008-08-25 |
2012-01-12 |
ジェネリクス・(ユーケー)・リミテッド |
スニチニブの新規な多形およびその調製方法
|
JP2012500837A
(ja)
*
|
2008-08-25 |
2012-01-12 |
ジェネリクス・(ユーケー)・リミテッド |
新規な結晶型およびその調製方法
|
MX2011002498A
(es)
*
|
2008-09-05 |
2011-08-04 |
Imp Innovations Ltd |
Derivados de isatina para uso como agentes de formacion de imagenes in vivo.
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
AR073807A1
(es)
*
|
2008-10-10 |
2010-12-01 |
Medichem Sa |
Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria.
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
EP2186809A1
(en)
*
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
US20100222371A1
(en)
*
|
2008-11-20 |
2010-09-02 |
Children's Medical Center Corporation |
Prevention of surgical adhesions
|
WO2010064611A1
(ja)
|
2008-12-01 |
2010-06-10 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
TW201028410A
(en)
|
2008-12-22 |
2010-08-01 |
Astrazeneca Ab |
Chemical compounds 610
|
EP2379595A2
(en)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Targeted binding agents directed to 5 1 and uses thereof
|
EP2373643A4
(en)
|
2009-01-02 |
2013-08-07 |
Hetero Research Foundation |
NEW SUNITINIB MALATE POLYMORPHS
|
KR102187034B1
(ko)
|
2009-01-16 |
2020-12-04 |
엑셀리시스, 인코포레이티드 |
암 치료용 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
|
JP5977522B2
(ja)
|
2009-02-05 |
2016-08-24 |
イミュノジェン・インコーポレーテッド |
新規ベンゾジアゼピン誘導体
|
CA2748943A1
(en)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
US9265764B2
(en)
*
|
2009-02-27 |
2016-02-23 |
Massachusetts Institute Of Technology |
Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
|
US20100222381A1
(en)
|
2009-02-27 |
2010-09-02 |
Hariprasad Vankayalapati |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
US8785457B2
(en)
|
2009-03-13 |
2014-07-22 |
Cellzome Limited |
Pyrimidine derivatives as mTOR inhibitors
|
WO2010108503A1
(en)
|
2009-03-24 |
2010-09-30 |
Life & Brain Gmbh |
Promotion of neuronal integration in neural stem cell grafts
|
EP2419423A1
(en)
|
2009-04-14 |
2012-02-22 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
WO2010120386A1
(en)
|
2009-04-17 |
2010-10-21 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
EP2255792A1
(en)
|
2009-05-20 |
2010-12-01 |
Ratiopharm GmbH |
Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
|
US8211901B2
(en)
|
2009-05-22 |
2012-07-03 |
Shenzhen Chipscreen Biosciences Ltd. |
Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
EP2264027A1
(en)
*
|
2009-05-27 |
2010-12-22 |
Ratiopharm GmbH |
Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
CN101906076B
(zh)
|
2009-06-04 |
2013-03-13 |
深圳微芯生物科技有限责任公司 |
作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
FR2948940B1
(fr)
*
|
2009-08-04 |
2011-07-22 |
Servier Lab |
Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
EP2475648A1
(en)
|
2009-09-11 |
2012-07-18 |
Cellzome Limited |
Ortho substituted pyrimidine compounds as jak inhibitors
|
EP2477978A1
(en)
|
2009-09-16 |
2012-07-25 |
Ranbaxy Laboratories Limited |
Salts of sunitinib
|
NZ598907A
(en)
|
2009-10-20 |
2014-03-28 |
Cellzome Ltd |
Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
|
US20120271056A1
(en)
|
2009-11-12 |
2012-10-25 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
|
US8916716B2
(en)
|
2009-11-19 |
2014-12-23 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
|
SI3279215T1
(sl)
|
2009-11-24 |
2020-07-31 |
Medimmune Limited |
Usmerjena vezavna sredstva proti B7-H1
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
WO2013022801A1
(en)
|
2011-08-05 |
2013-02-14 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
WO2011095802A1
(en)
|
2010-02-02 |
2011-08-11 |
Generics [Uk] Limited |
Hplc method for analyzing sunitinib
|
WO2011100325A2
(en)
*
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
KR20130009760A
(ko)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Cd20 항체 및 이의 용도
|
RU2012139182A
(ru)
|
2010-02-22 |
2014-03-27 |
Ф. Хоффманн-Ля Рош Аг |
ПИРИДО[3,2-d]ПИРИМИДИНЫ - ИНГИБИТОРЫ PI3К ДЕЛЬТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
WO2011104555A2
(en)
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
EP2542536B1
(en)
|
2010-03-04 |
2015-01-21 |
Cellzome Limited |
Morpholino substituted urea derivatives as mtor inhibitors
|
AU2011222470A1
(en)
|
2010-03-04 |
2012-09-27 |
Ranbaxy Laboratories Limited |
Process for the direct preparation of malic acid salt of sunitinib
|
EP2545034A1
(en)
|
2010-03-10 |
2013-01-16 |
Synthon B.V. |
A process for amidation of pyrrole carboxylate compounds
|
CA2793359A1
(en)
|
2010-03-18 |
2011-09-22 |
Ranbaxy Laboratories Limited |
Process for the preparation of malic acid salt of sunitinib
|
EP2550263A4
(en)
|
2010-03-23 |
2013-07-24 |
Univ Johns Hopkins |
COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
|
WO2011128699A2
(en)
*
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
EP2566867A1
(en)
|
2010-04-30 |
2013-03-13 |
Cellzome Limited |
Pyrazole compounds as jak inhibitors
|
WO2011138565A1
(fr)
|
2010-05-05 |
2011-11-10 |
Biorebus |
Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
|
EP2392324A1
(en)
|
2010-06-01 |
2011-12-07 |
Societe De Coordination De Recherches Therapeutiques |
Rhenium complexes and their pharmaceutical use
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
RU2560683C2
(ru)
|
2010-06-25 |
2015-08-20 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
|
WO2012000970A1
(en)
|
2010-07-01 |
2012-01-05 |
Cellzome Limited |
Triazolopyridines as tyk2 inhibitors
|
CN103097418A
(zh)
|
2010-07-09 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
抗神经毡蛋白抗体及使用方法
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
WO2012022681A2
(en)
|
2010-08-20 |
2012-02-23 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
|
US8426418B2
(en)
|
2010-08-27 |
2013-04-23 |
CollabRx Inc. |
Method to treat melanoma in BRAF inhibitor-resistant subjects
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
US8846953B2
(en)
|
2010-11-01 |
2014-09-30 |
Scinopharm Taiwan, Ltd. |
Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
|
WO2012059941A1
(en)
*
|
2010-11-04 |
2012-05-10 |
Ind-Swift Laboratories Limited |
Process for preparation of sunitinib malate and salts thereof
|
EP2638018A1
(en)
|
2010-11-09 |
2013-09-18 |
Cellzome Limited |
Pyridine compounds and aza analogues thereof as tyk2 inhibitors
|
EP2640384A1
(en)
|
2010-11-18 |
2013-09-25 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
CA2818612C
(en)
|
2010-11-19 |
2020-12-29 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
TWI410425B
(zh)
|
2010-12-03 |
2013-10-01 |
Lilly Co Eli |
唑并[5,4-b]吡啶-5-基化合物
|
US9827326B2
(en)
*
|
2010-12-23 |
2017-11-28 |
Nektar Therapeutics |
Polymer-sunitinib conjugates
|
JP6009457B2
(ja)
|
2010-12-23 |
2016-10-19 |
ネクター セラピューティクス |
ポリマー−デスエチルスニチニブコンジュゲート
|
AU2012213080B2
(en)
|
2011-01-31 |
2014-03-27 |
Novartis Ag |
Novel heterocyclic derivatives
|
ES2717657T3
(es)
|
2011-02-15 |
2019-06-24 |
Immunogen Inc |
Métodos para la preparación de conjugados
|
AU2012216893B2
(en)
|
2011-02-17 |
2016-08-11 |
Cancer Therapeutics Crc Pty Limited |
FAK inhibitors
|
WO2012110774A1
(en)
|
2011-02-17 |
2012-08-23 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
US8630703B2
(en)
|
2011-03-09 |
2014-01-14 |
Technion Research & Development Foundation Limited |
Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
|
CN102115469A
(zh)
*
|
2011-03-21 |
2011-07-06 |
浙江大学 |
吲哚啉-2-酮类衍生物的制备和用途
|
EP2694511A1
(en)
|
2011-04-04 |
2014-02-12 |
Cellzome Limited |
Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
|
KR20140027972A
(ko)
|
2011-04-08 |
2014-03-07 |
베타 파마, 인크. |
신규 인돌리논 단백질 키나제 억제제
|
WO2012143320A1
(en)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
CN102898402B
(zh)
*
|
2011-04-26 |
2016-01-20 |
北京大学 |
一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
EP3812387A1
(en)
|
2011-07-21 |
2021-04-28 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
KR20140047092A
(ko)
|
2011-07-28 |
2014-04-21 |
셀좀 리미티드 |
Jak 억제제로서의 헤테로시클릴 피리미딘 유사체
|
WO2013017479A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017480A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
JP2014531449A
(ja)
|
2011-09-20 |
2014-11-27 |
セルゾーム リミティッド |
キナーゼ阻害剤としてのピラゾロ[4,3―c]ピリジン誘導体
|
CA2849189A1
(en)
|
2011-09-21 |
2013-03-28 |
Cellzome Limited |
Morpholino substituted urea or carbamate derivatives as mtor inhibitors
|
MX341577B
(es)
|
2011-10-07 |
2016-08-25 |
Cellzome Ltd |
Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
|
CN102499917B
(zh)
|
2011-10-25 |
2014-12-17 |
澳门大学 |
吲哚酮类化合物在制备神经保护药物中的应用
|
CN104039790B
(zh)
|
2011-10-28 |
2016-04-13 |
诺华股份有限公司 |
嘌呤衍生物及它们在治疗疾病中的应用
|
CN103130774B
(zh)
*
|
2011-11-22 |
2016-06-22 |
齐鲁制药有限公司 |
具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
|
CN103127096B
(zh)
*
|
2011-12-02 |
2015-11-25 |
杨子娇 |
吡咯基取代的吲哚类化合物在治疗青光眼病的应用
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
WO2013092854A1
(en)
|
2011-12-23 |
2013-06-27 |
Cellzome Limited |
Pyrimidine-2,4-diamine derivatives as kinase inhibitors
|
CN102491932A
(zh)
*
|
2011-12-26 |
2012-06-13 |
天津科技大学 |
一种3-吲哚啉酮类衍生物及其制备方法及其应用
|
WO2013140232A1
(en)
|
2012-03-23 |
2013-09-26 |
Laurus Labs Private Limited |
An improved process for the preparation of sunitinib and its acid addition salts thereof
|
IN2014MN02105A
(US06573293-20030603-C00090.png)
|
2012-04-20 |
2015-09-11 |
Annji Pharm Co Ltd |
|
CN102653521B
(zh)
*
|
2012-04-27 |
2014-08-06 |
首都师范大学 |
吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途
|
PL399027A1
(pl)
|
2012-04-27 |
2013-10-28 |
Instytut Farmaceutyczny |
Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
|
RU2609651C2
(ru)
|
2012-05-04 |
2017-02-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
SG11201406550QA
(en)
|
2012-05-16 |
2014-11-27 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
SI2859017T1
(sl)
|
2012-06-08 |
2019-05-31 |
Sutro Biopharma, Inc. |
Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe
|
EP3135690A1
(en)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
US9238644B2
(en)
|
2012-08-17 |
2016-01-19 |
Cancer Therapeutics Crc Pty Limited |
VEGFR3 inhibitors
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
ES2907763T3
(es)
|
2012-08-31 |
2022-04-26 |
Sutro Biopharma Inc |
Aminoácidos modificados que comprenden un grupo azido
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014045101A1
(en)
|
2012-09-21 |
2014-03-27 |
Cellzome Gmbh |
Tetrazolo quinoxaline derivatives as tankyrase inhibitors
|
WO2014062838A2
(en)
|
2012-10-16 |
2014-04-24 |
Tolero Pharmaceuticals, Inc. |
Pkm2 modulators and methods for their use
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
CN104755463A
(zh)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
非晶态形式的喹啉衍生物及其生产方法
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
JP6423804B2
(ja)
|
2013-02-28 |
2018-11-14 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤を含む複合体
|
KR20150127249A
(ko)
*
|
2013-03-13 |
2015-11-16 |
보스톤 바이오메디칼, 인크. |
암 치료를 위한 암 줄기세포 경로 키나아제의 저해제로서 3-(아릴 또는 헤테로아릴)메틸렌인돌린-2-온 유도체
|
CA2905993C
(en)
|
2013-03-14 |
2022-12-06 |
Tolero Pharmaceuticals, Inc. |
Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
|
WO2014152959A1
(en)
|
2013-03-14 |
2014-09-25 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
CN104119321B
(zh)
*
|
2013-04-28 |
2017-09-08 |
齐鲁制药有限公司 |
二氢吲哚酮衍生物的二马来酸盐及其多晶型物
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
FR3008411B1
(fr)
*
|
2013-07-12 |
2015-07-03 |
Servier Lab |
Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
|
DK3039424T3
(da)
|
2013-08-28 |
2020-08-31 |
Crown Bioscience Inc Taicang |
Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
CA2838587A1
(en)
|
2013-10-18 |
2015-04-18 |
Hari Babu Matta |
Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
|
US9278955B2
(en)
|
2013-10-18 |
2016-03-08 |
Sun Pharmaceutical Industries Limited |
Ascorbic acid salt of sunitinib
|
MY182168A
(en)
|
2013-11-01 |
2021-01-18 |
Pfizer |
Vectors for expression of prostate-associated antigens
|
DK3076969T3
(da)
|
2013-12-06 |
2021-11-22 |
Novartis Ag |
Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
|
CN104829596B
(zh)
|
2014-02-10 |
2017-02-01 |
石家庄以岭药业股份有限公司 |
吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
|
CN103923014A
(zh)
*
|
2014-05-05 |
2014-07-16 |
宁夏宝马药业有限公司 |
环肌酸制备方法
|
EP3177289A4
(en)
|
2014-08-08 |
2018-03-21 |
Forsight Vision4, Inc. |
Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
|
EP4089076A1
(en)
|
2014-08-28 |
2022-11-16 |
Eisai R&D Management Co., Ltd. |
High-purity quinoline derivative and method for manufacturing same
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
CN113181362B
(zh)
|
2015-01-13 |
2023-06-13 |
国立大学法人京都大学 |
用于预防和/或治疗肌萎缩性侧索硬化症的药剂
|
CA2976325C
(en)
|
2015-02-25 |
2023-07-04 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
BR112017022666A8
(pt)
|
2015-04-20 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Preparando resposta à alvocidib por perfilamento mitocondrial
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
ES2921350T3
(es)
|
2015-05-18 |
2022-08-24 |
Sumitomo Pharma Oncology Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
KR20180018695A
(ko)
|
2015-06-16 |
2018-02-21 |
가부시키가이샤 프리즘 파마 |
항암제
|
WO2017024073A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
JP2018536017A
(ja)
|
2015-09-22 |
2018-12-06 |
グレイバグ ビジョン インコーポレイテッド |
眼障害の治療のための化合物及び組成物
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
CA3002954A1
(en)
|
2015-11-02 |
2017-05-11 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
WO2017083779A1
(en)
|
2015-11-12 |
2017-05-18 |
Graybug Vision, Inc. |
Aggregating microparticles for therapy
|
CN109069664B
(zh)
|
2016-01-27 |
2022-05-13 |
苏特罗生物制药公司 |
抗cd74抗体偶联物,包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
|
CA3012718A1
(en)
|
2016-02-08 |
2017-08-17 |
Vitrisa Therapeutics, Inc. |
Compositions with improved intravitreal half-life and uses thereof
|
EP3228630A1
(en)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
|
CN107459519A
(zh)
|
2016-06-06 |
2017-12-12 |
上海艾力斯医药科技有限公司 |
稠合嘧啶哌啶环衍生物及其制备方法和应用
|
WO2018045379A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
CN110167924A
(zh)
|
2016-10-28 |
2019-08-23 |
西奈山伊坎医学院 |
用于治疗ezh2介导的癌症的组合物和方法
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
ES2906439T3
(es)
|
2016-12-05 |
2022-04-18 |
Apros Therapeutics Inc |
Compuestos de pirimidina que contienen grupos ácidos
|
CN110267659A
(zh)
|
2016-12-08 |
2019-09-20 |
西奈山伊坎医学院 |
用于治疗cdk4/6介导的癌症的组合物和方法
|
AU2017379847B2
(en)
|
2016-12-19 |
2022-05-26 |
Sumitomo Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
CN106916143B
(zh)
*
|
2017-03-14 |
2019-09-27 |
哈尔滨医科大学 |
一种预防和治疗冠心病的药物及其应用
|
CA3056923A1
(en)
|
2017-03-23 |
2018-09-27 |
Graybug Vision, Inc. |
Drugs and compositions for the treatment of ocular disorders
|
JP2020519585A
(ja)
|
2017-05-10 |
2020-07-02 |
グレイバグ ビジョン インコーポレイテッド |
医学療法のための延長放出マイクロ粒子及びその懸濁液
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
MX2020002666A
(es)
|
2017-09-18 |
2020-11-06 |
Sutro Biopharma Inc |
Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
JP2021515013A
(ja)
|
2018-03-06 |
2021-06-17 |
アイカーン スクール オブ メディスン アット マウント シナイ |
セリンスレオニンキナーゼ(akt)分解/破壊化合物および使用方法
|
EP3539536A1
(en)
|
2018-03-15 |
2019-09-18 |
MH10 Spolka z ograniczona odpowiedzialnoscia |
A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
|
JP7351859B2
(ja)
|
2018-06-04 |
2023-09-27 |
アプロス セラピューティクス, インコーポレイテッド |
Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
US11040038B2
(en)
|
2018-07-26 |
2021-06-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
CN113490499A
(zh)
|
2018-12-04 |
2021-10-08 |
大日本住友制药肿瘤公司 |
用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
|
JPWO2020130125A1
(ja)
|
2018-12-21 |
2021-11-04 |
第一三共株式会社 |
抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
|
AU2020221247A1
(en)
|
2019-02-12 |
2021-08-05 |
Sumitomo Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
KR20210142154A
(ko)
|
2019-03-21 |
2021-11-24 |
옹쎄오 |
암 치료를 위한 키나제 억제제와 조합된 dbait 분자
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
EP3958845A1
(en)
|
2019-04-25 |
2022-03-02 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous sunitinib
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
WO2020227325A1
(en)
|
2019-05-06 |
2020-11-12 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of hpk1
|
JP2022545930A
(ja)
|
2019-08-31 |
2022-11-01 |
上海奕拓醫藥科技有限責任公司 |
Fgfr阻害剤とするピラゾール類誘導体及びその調製方法
|
US20220401436A1
(en)
|
2019-11-08 |
2022-12-22 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
CN111233841A
(zh)
*
|
2020-03-17 |
2020-06-05 |
湖北扬信医药科技有限公司 |
一种舒尼替尼有关物质及其制备方法和用途
|
WO2023278424A1
(en)
*
|
2021-06-28 |
2023-01-05 |
The Regents Of The University Of California |
Methods for treating and ameliorating t cell related diseases
|
CN113717159A
(zh)
*
|
2021-09-16 |
2021-11-30 |
中国药科大学 |
吲哚酮类化合物及其药物组合物、制备方法及用途
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024017372A1
(zh)
*
|
2022-07-22 |
2024-01-25 |
成都百裕制药股份有限公司 |
一种吲哚酮衍生物及其应用
|